Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: A meta-analysis

Antiviral Therapy

Volumn 14, Issue 8, 2009, Pages 1139-1148

  Slavenburg, Serena ^a   Weggelaar, Ines ^a   Van Oijen, Martijn G H ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERONS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 73449094187     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1464     Document Type: Article

References (26)

1. L auer GM, Walker BD. Hepatitis C infection. N Engl J Med 2001; 345:41-52.
2. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
3. De Bruijne J, Buster EH, Gelderblom HC, et al. Treatment of chronic hepatitis C virus infection - Dutch national guidelines. Neth J Med 2008; 66:311-322.
4. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
5. Fontanges T, Beorchia S, Douvin C, et al. Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection. Gastroenterol Clin Biol 2007; 31:566-572.
6. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357:124-134.
7. Zekry A, Patel K, Muir A, et al. Tinkering and tailoring with HCV therapy: can we get away with less? Hepatology 2004; 40:1249-1251.
8. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-2617.
9. L agging M, Langeland N, Pedersen C, et al. Randomised comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47:1837-1845.
10. Dalgard O, Bjøro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47:35-42.
11. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
12. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28:397-404.
13. Andriulli A, Dalgard O, Bjøro K, et al. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Dig Liver Dis 2006; 38:741-748.
14. Dalgard O, Bjøro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40:1260-1265.
15. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354:1896-1900.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12.
17. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56:553-559.
18. Farooqi JI, Farooqi RJ. Conventional interferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. Asian Pacific Digestive Week. 15-18 October 2007, Kobe, Japan. Abstract 218.
19. Mecenate F, Barbaro G, Pellicelli A, et al. Comparison of peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2 or 3: the Cleo Trial. 58th Annual Meeting of the American Association for the Study of Liver Diseases. 2-6 November 2007, Boston, MA, USA. Abstract 1327.
20. Bonardi R, Manca A, Tabone M, et al. The efficacy of a 12 weeks course of pegylated interferon alpha-2b (Peg-IFN) and ribavirin (RBV) is similar to a standard 24 weeks course, regardless of basal viremic level. 9th Annual Meeting of the European Society for Clinical Virology. 3-6 September 2006, Birmingham, UK. Abstract 246.
21. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30:787-793.
22. Muir AJ, Bornstein JD, Killenberg PG, the Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350:2265-2271.
23. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
24. Shiffman ML, Wilson M, Salvatori J, et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 with peginterferon alfa-2b (PEGIFN), high weight based dose ribavirin (RVN) and epoetin alfa (EPO) enhances sustained virologic response (SVR). Hepatology 2005; 42:217.
25. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008; 15:475-481.
26. Toyoda H, Kumada T, Kiriyama S, et al. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response. Liver Int 2009; 29:120-125.